Journal
ACTA HAEMATOLOGICA
Volume 144, Issue 5, Pages 508-518Publisher
KARGER
DOI: 10.1159/000514071
Keywords
Chronic lymphocytic leukemia; Coronavirus disease 2019; Infections; Immunodeficiency
Categories
Ask authors/readers for more resources
The novel coronavirus, SARS-CoV-2, was first identified in Wuhan, China in December 2019, leading to a global pandemic. Cancer patients, especially those with chronic lymphocytic leukemia (CLL), are at higher risk for severe SARS-CoV-2 infections due to their impaired immune systems. Treatment initiation can further increase the risk of severe infections for CLL patients.
The novel severe acute respiratory syndrome coronavirus (SARS-CoV-2) has been first described in December 2019 in Wuhan, China, and has led to a worldwide pandemic ever since. Initial clinical data imply that cancer patients are particularly at risk for a severe course of SARS-CoV-2. In patients with chronic lymphocytic leukemia (CLL), infections are a main contributor to morbidity and mortality driven by an impaired immune system. Treatment initiation is likely to induce immune modulation that further increases the risk for severe infections. This article aims to give an overview on pathogenesis and risk of infectious complications in patients with CLL. In this context, we discuss current data of SARS-CoV-2 infections in patients with CLL and how the pandemic impacts their management.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available